Fasenra benralizumab

The 8-week dosing gap is Fasenra's single biggest adherence and satisfaction leak: patients report 2-3 weeks of symptom relapse before each maintenance injection, creating a predictable switching trigger toward more frequent biologics.

• Fasenra delivers dramatic, often immediate steroid-sparing relief that patients describe as transformative, but the 8-week maintenance interval creates a recurring 2-3 week symptom trough that drives dissatisfaction and switching inquiries.
• Joint pain, fatigue, and hair thinning emerging after year one are the top unlabeled side-effect complaints in the corpus, and specialists dismissing these concerns is a documented trust-erosion moment for younger patients.
• Cost and Medicare access dominate the decision-making conversation for older patients, with out-of-pocket estimates of $1,800 to $17,000 per injection circulating in forums and blocking initiation for commercially-uninsured populations.
• The June 2024 EGPA approval and May 2026 HES approval are generating a new wave of rare-disease patient questions that current patient-support materials were not designed to answer, opening a peer-community gap.